Here, we describe a novel mode of cooperation of EGFR and FAK signalling, which converge on ezrin, and has provided the opportunity to investigate possible treatments such as targeting FAK and/or ezrin in combination with EGFR to overcome EGFR TKI resistance in cancer cells. Here, PTK2 is linked to cancer.